The two sides of Hippo pathway in cancer

Semin Cancer Biol. 2022 Oct:85:33-42. doi: 10.1016/j.semcancer.2021.07.006. Epub 2021 Jul 13.

Abstract

The Hippo signaling pathway was originally characterized by genetic studies in Drosophila to regulate tissue growth and organ size, and the core components of this pathway are highly conserved in mammals. Studies over the past two decades have revealed critical physiological and pathological functions of the Hippo tumor-suppressor pathway, which is tightly regulated by a broad range of intracellular and extracellular signals. These properties enable the Hippo pathway to serve as an important controller in organismal development and adult tissue homeostasis. Dysregulation of the Hippo signaling has been observed in many cancer types, suggesting the possibility of cancer treatment by targeting the Hippo pathway. The general consensus is that Hippo has tumor suppressor function. However, growing evidence also suggests that the function of the Hippo pathway in malignancy is cancer context dependent as recent studies indicating tumor promoting function of LATS. This article surveys the Hippo pathway signaling mechanisms and then reviews both the tumor suppressing and promoting function of this pathway. A comprehensive understanding of the dual roles of the Hippo pathway in cancer will benefit future therapeutic targeting of the Hippo pathway for cancer treatment.

Keywords: Hippo pathway; LATS1/2; Oncoprotein; Tumor suppressor; YAP/TAZ.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Drosophila
  • Hippo Signaling Pathway
  • Humans
  • Mammals
  • Neoplasms* / genetics
  • Protein Serine-Threonine Kinases*
  • Signal Transduction

Substances

  • Protein Serine-Threonine Kinases